Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Wanbury Limited ( (IN:WANBURY) ).
Wanbury Limited’s board has approved the unaudited financial results for the quarter and nine months ending December 31, 2024. Additionally, the company plans to raise INR 175 crore through the issuance of non-convertible debentures in a private placement, and it has granted 200,000 stock options to employees under its ESOP 2016 scheme. These actions are likely to strengthen Wanbury’s financial position and incentivize its workforce, potentially enhancing its market competitiveness.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the production and marketing of active pharmaceutical ingredients (APIs), formulations, and contract research and manufacturing services. The company primarily serves both domestic and international markets.
YTD Price Performance: -27.70%
Average Trading Volume: 22,819
Current Market Cap: 7.55B INR
Find detailed analytics on WANBURY stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue